EXACT Sciences Corporation (NASDAQ:EXAS) announced that the company generated revenues of $21.2 million during the second quarter ended June 30, 2016, representing a 161-percent increase from $8.1 million in the second quarter of 2015. The company completed approximately 54,000 Cologuard tests during the second quarter, an increase of approximately 160 percent compared to the 21,000 tests completed during the same period of 2015. Since Cologuard’s launch and through the end of the second quarter of 2016, approximately 41,000 physicians have ordered the test.

“Continued execution of our sales and direct-to-consumer marketing strategies during the second quarter drove an increase in new physicians ordering Cologuard and broader patient awareness and demand for our non-invasive colon cancer screening test,” said Kevin Conroy, chairman and CEO of Exact Sciences. “As a result, we delivered another strong quarterly financial performance, highlighted by robust annualized revenue growth, a sequential increase in completed tests that exceeded our expectations, and solid expense control and favorable cash utilization.”

The company’s direct-to-consumer marketing strategy combines a targeted internet and social media-based effort with a national television advertising campaign. During the second half of the year, the company will continue to invest in both to drive further physician and patient awareness of Cologuard.

Increasing commercial insurance coverage of Cologuard remains a key component of Exact Sciences’ growth strategy. During the second quarter, the U.S. Preventive Services Task Force issued its final recommendations for colorectal cancer screening, which assigned an A grade for screening average-risk individuals ages 50 to 75. Cologuard is listed among the seven screening methods recommended by the task force.

“We anticipate that Cologuard’s position in the final recommendations will have a meaningful, positive long-term effect on our efforts to expand commercial insurance coverage,” Mr. Conroy said. “Commercial insurers typically cover cancer screening tests recommended by the task force and we are engaged in active discussions with insurers to cover Cologuard.”

Cologuard is covered for 58 percent of its estimated total addressable population, men and women between the ages of 50 and 85 at average risk of colon cancer.

Cologuard’s patient compliance rate was 68 percent as of June 30, 2016. The compliance rate is derived from the number of valid tests reported divided by the number of collection kits shipped to patients during the 12-month period ending 60 days prior to June 30, 2016. Cologuard’s compliance rate may vary from quarter to quarter, reflecting, among other factors, changes in the mix of the insurance coverage of patients completing the test.


The company continues to anticipate completing more than 240,000 Cologuard tests during 2016, generating revenue of $90 to $100 million.

The company’s guidance for revenue and completed tests are forward-looking statements. They are subject to various risks and uncertainties that could cause the company’s actual results to differ materially from the anticipated targets. See the cautionary information about forward-looking statements in the “Safe-Harbor Statement” section of this news release.

Financial Results

Exact Sciences reported total revenues of $21.2 million for the second quarter of 2016, compared to $8.1 million for the same period of 2015.  Average recognized revenue per test totaled $391 during the second quarter of 2016.

The company reported a net loss of $44.8 million, or ($0.46) per share for the second quarter of 2016. The company reported a net loss of ($39.1) million, or ($0.44) per share, for the same period of 2015.

Operating expenses for the second quarter of 2016 were $56.2 million, compared to $42.4 million for the same period in 2015.

Cash utilization during the second quarter of 2016 totaled $38.5 million. Exact Sciences ended the second quarter of 2016 with cash, cash equivalents and marketable securities totaling $224.1 million, compared to $262.6 million at March 31, 2016. (Original Source)

Shares of Exact Sciences are up nearly 18% to $14.65 in pre-market trading. EXAS has a 1-year high of $25 and a 1-year low of $4.67. The stock’s 50-day moving average is $10.99 and its 200-day moving average is $7.59.

On the ratings front, Exact Sciences has been the subject of a number of recent research reports. In a report issued on July 13, Craig-Hallum analyst William Bonello reiterated a Buy rating on EXAS, with a price target of $18, which implies an upside of 44.5% from current levels. Separately, on July 6, BTIG’s Sean Lavin reiterated a Buy rating on the stock and has a price target of $13.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, William Bonello and Sean Lavin have a total average return of -2.6% and 13.9% respectively. Bonello has a success rate of 52.9% and is ranked #3016 out of 4079 analysts, while Lavin has a success rate of 69.3% and is ranked #78.

The street is mostly Bullish on EXAS stock. Out of 9 analysts who cover the stock, 6 suggest a Buy rating and 3 recommend to Hold the stock. The 12-month average price target assigned to the stock is $11.00, which reflects a potential downside of -11.7% from last closing price.

EXACT Sciences Corp. is a molecular diagnostics company, which is focused on the early detection and prevention of colorectal cancer. It has an intellectual property, which protects its non invasive, molecular screening technology for the detection of colorectal cancer.